Approvals Granted to Begin LYS-GM101 Clinical Trial for GM1 Gangliosidosis
source: pixabay.com

Approvals Granted to Begin LYS-GM101 Clinical Trial for GM1 Gangliosidosis

In an exciting press release, gene therapy platform company Lysogene announced that it had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee. As…

Continue Reading Approvals Granted to Begin LYS-GM101 Clinical Trial for GM1 Gangliosidosis